Completing data — refresh the page later to see the latest
19600-01-2CCCCCCCCCCCCC/C=C/[C@H](O)[C@@H](CO[C@@H]1O[C@@H](CO)[C@H](O[C@H]2O[C@@H](CO)[C@@H](O[C@H]3O[C@@H](CO)[C@@H](O)[C@@H](O)[C@@H]3NC(C)=O)[C@@H](OC[C@@]3(C(=O)O)C[C@@H](O)[C@H](NC(C)=O)[C@@H]([C@@H](O)[C@@H](O)CO)O3)[C@@H]2O)[C@@H](O)[C@@H]1O)NC(=O)CCCCCCCCCCCCCCCCCUSMMPBVNWHAJBE-YMEOXFOQSA-NGanglioside GM2 is a glycosphingolipid antigen expressed by a variety of human cancer cells. GM2 containing vaccines have been shown to elicit antibodies production in melanoma patients without deleterious effects associated with an immune response to GM2. Mutations in at least 1 of 3 recessive genes: HEXA, HEXB, and GM2A cause defects in GM2 catabolism, leading to lysosomal lipid storage disorders that manifest primarily as neurodegenerative diseases, including Tay-Sachs and Sandhoff Disease.
19600-01-2DTXSID501027450Safety information is for reference only and does not replace the supplier’s Safety Data Sheet (SDS), applicable regulations, or professional assessment.